The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated continuing benefit in overall survival (OS) and progression-free survival (PFS) for patients with BRAF V600—mutant melanoma, according to an updated analysis of the COLUMBUS (NCT01909453) trial during a poster presentation at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Conferences
Autologous Tumor-Infiltrating Lymphocytes Effective for Treatment of Metastatic Melanoma
Lifileucel (LN-144) showed a favorable overall response rate in patients with pretreated metastatic melanoma, according to initial data from cohort 4 of the phase 2 C-144-01 trial.
Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care.
Melanoma tumor syndromes
Recognition of patients with hereditary melanoma is important not only because these individuals require careful surveillance for future primary melanomas, but also because they may be predisposed to multiple other types of malignancies because of their genetic mutation, says Hensin Tsao, M.D., Ph.D., professor of dermatology and director, MGH Melanoma and Pigmented Lesion Center, Massachusetts General Hospital, Harvard Medical School, Boston.